Last Price$4.3(4.0%)
Market Cap$211.4B
SLN Intrinsic Value
Intrinsic Value of SLN Overview
Key Highlights:
As of Mar 03, 2025 SLN Relative Value is $0.0, which is overvalued by 99.7%, compared to current share price of $4.3.
As of Mar 03, 2025 SLN DCF Value is N/A, which is undervalued by N/A, compared to current share price of $4.3.
SLN Historical Intrinsic Value
Crunching data... Almost there!
Crunching data... Almost there!
SLN Valuation Metrics
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
10,233.8x (as of Mar 03, 2025)
EV/Gross Profit
22,855.0x (as of Mar 03, 2025)
EV/EBIT
(2,850.8x) (as of Mar 03, 2025)
EV/EBITDA
(2,890.1x) (as of Mar 03, 2025)
EV/FCF
(3,782.8x) (as of Mar 03, 2025)
EV/OCF
(3,792.9x) (as of Mar 03, 2025)
P/Revenue
10,241.7x (as of Mar 03, 2025)
P/Gross Profit
22,872.7x (as of Mar 03, 2025)
P/EBIT
(2,853.1x) (as of Mar 03, 2025)
P/EBITDA
(2,892.3x) (as of Mar 03, 2025)
P/FCF
(3,785.7x) (as of Mar 03, 2025)
P/OCF
(3,795.9x) (as of Mar 03, 2025)
P/E
(2,826.5x) (as of Mar 03, 2025)
P/BV
1,760.3x (as of Mar 03, 2025)
PEG 1Y
44.1x (as of Mar 03, 2025)
SLN DCF Model
Free Cash Flow to Firm Model
NOPAT Model
Free Cash Flow to Equity Model
Net Income Model
Millions
Billions
| Dec'19 Actual | Dec'20 Actual | Dec'21 Actual | Dec'22 Actual | Dec'23 Actual | Dec'24 Estimate | Dec'25 Estimate | Dec'26 Estimate | Dec'27 Estimate | Dec'28 Estimate | Dec'29 Estimate | Dec'30 Estimate | Dec'31 Estimate | Dec'32 Estimate | Dec'33 Estimate | Dec'34 Terminal | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.2 (24,400,100.0%) | 5.5 2,145.5% | 12.4 126.6% | 17.5 41.0% | 25.4 45.0% | 20.7 (18.3%) | 27.6 33.3% | 16.7 (39.5%) | 58.2 247.9% | 163.1 180.3% | 409.0 150.8% | 904.9 121.2% | 1,734.4 91.7% | 2,811.7 62.1% | 3,727.0 32.6% | 3,838.8 3.0% |
% margin | (22.7) (9,317.2%) | (35.8) (654.3%) | (45.8) (369.0%) | (48.6) (277.7%) | (49.6) (195.5%) | (20.7) (100.0%) | (27.6) (100.0%) | (16.7) (100.0%) | (58.2) (100.0%) | (163.1) (100.0%) | (409.0) (100.0%) | (904.9) (100.0%) | (1,734.4) (100.0%) | (2,811.7) (100.0%) | (3,727.0) (100.0%) | (3,838.8) (100.0%) |
NOPAT % effective tax rate | (19.5) (7,977.7%) | (32.4) (590.8%) | (39.4) (317.1%) | (41.5) (237.3%) | (42.7) (168.1%) | (17.8) (86.0%) | (23.8) (86.0%) | (14.4) (86.0%) | (50.0) (86.0%) | (140.3) (86.0%) | (351.8) (86.0%) | (778.2) (86.0%) | (1,491.6) (86.0%) | (2,418.0) (86.0%) | (3,205.3) (86.0%) | (3,301.4) (86.0%) |
% of revenue | 0.5 197.5% | 0.5 9.1% | 0.4 3.4% | 0.5 2.8% | 0.5 2.0% | 0.6 2.7% | 0.8 2.7% | 0.5 2.7% | 1.6 2.7% | 4.4 2.7% | 11.1 2.7% | 24.6 2.7% | 47.2 2.7% | 76.4 2.7% | 101.3 2.7% | 104.4 2.7% |
% of revenue | (0.0) (3.7%) | (0.5) (9.4%) | (1.3) (10.7%) | (0.4) (2.5%) | (0.0) (0.2%) | (0.9) (4.5%) | (1.2) (4.5%) | (0.7) (4.5%) | (2.6) (4.5%) | (7.3) (4.5%) | (18.3) (4.5%) | (40.5) (4.5%) | (77.7) (4.5%) | (125.9) (4.5%) | (166.9) (4.5%) | (171.9) (4.5%) |
% of revenue | 21.1 8,641.4% | 18.7 340.5% | 38.8 312.9% | (8.3) (47.2%) | (11.7) (46.0%) | 15.2 73.2% | 20.2 73.2% | 12.2 73.2% | 42.6 73.2% | 119.5 73.2% | 299.6 73.2% | 662.7 73.2% | 1,270.2 73.2% | 2,059.2 73.2% | 2,729.6 73.2% | 2,811.5 73.2% |
Free Cash Flow to Firm (FCFF) % of revenue | 2.1 857.6% | (13.7) (250.6%) | (1.4) (11.6%) | (49.8) (284.3%) | (53.9) (212.3%) | (3.0) (14.5%) | (4.0) (14.5%) | (2.4) (14.5%) | (8.4) (14.5%) | (23.7) (14.5%) | (59.4) (14.5%) | (131.4) (14.5%) | (251.9) (14.5%) | (408.3) (14.5%) | (541.3) (14.5%) | (557.5) (14.5%) |
% of FCFF used in calculation | ||||||||||||||||
Discount period | ||||||||||||||||
Discount factor | ||||||||||||||||
Discounted FCFF (DFCFF) |
SLN DCF Value
Crunching data... Almost there!
SLN Earnings Power Value and Enterprise Value
Annual
LTM
Enterprise Value Breakdown
EPV and MIVoG as % of EV
SLN Reverse DCF
Implied FCF growth
Implied Revenue growth
Reverse DCF Assumptions and Outputs
as of Sep 30, 2024
(58.8M)
Long-Term growth rate
3.0%
FX rate
1.3
Last share price
18.2
Implied FCF growth 1-10Y
0.0%
Implied Free Cash Flow growth vs Historical average vs Industry growth
Competing with SLN Intrinsic Value
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Enterprise Value | Intrinsic Value | DCF Value | Relative value | Ben Graham Revised fair value | Peter Lynch fair value | Earnings Power Value (EPV),
% of EV | Market-Implied Value of Growth (MIVoG),
% of EV | Reverse DCF (implied FCF growth) | Reverse DCF (implied Revenue growth) |
$211.4B | $211.2B | $0.0 99.8% overvalued | N/A | $0.0 99.8% overvalued | $48.7 1,026.8% undervalued | $0.1 98.6% overvalued | N/A | N/A | 0.0% | 0.0% | |
$402.0B | $412.7B | $60.0 32.9% overvalued | $78.4 12.0% overvalued | $41.5 53.5% overvalued | $82.0 8.3% overvalued | $72.8 18.5% overvalued | 49.0% | 51.0% | 10.0% | 9.6% | |
$125.5B | $121.2B | $195.0 59.6% overvalued | N/A | $195.0 59.6% overvalued | $1,733.5 258.7% undervalued | N/A | 7.1% | 92.9% | (100.0%) | (100.0%) | |
$74.0B | $58.1B | $1,013.8 48.0% undervalued | $1,343.4 96.0% undervalued | $684.3 0.1% overvalued | $578.5 15.5% overvalued | $370.8 45.9% overvalued | 71.7% | 28.3% | 1.6% | 2.0% | |
$38.1B | N/A | $109.1 82.5% overvalued | N/A | $109.1 82.5% overvalued | $204.8 67.1% overvalued | N/A | (12.2%) | 112.2% | (100.0%) | (100.0%) | |
$31.3B | $29.9B | $93.6 61.6% overvalued | N/A | $93.6 61.6% overvalued | $89.9 63.1% overvalued | N/A | (6.0%) | 106.0% | (100.0%) | 38.0% | |
$27.1B | $9,862.2M | $165.8 48.6% undervalued | $230.6 107.0% undervalued | $101.0 9.4% overvalued | $329.3 195.2% undervalued | N/A | (238.6%) | 338.6% | 2.5% | (12.4%) | |
$14.8B | $12.7B | $46.7 33.6% overvalued | $19.4 72.0% overvalued | $73.9 5.2% undervalued | $745.2 960.6% undervalued | $89.4 27.3% undervalued | 0.7% | 99.3% | 16.2% | 43.4% | |
$14.6B | $14.2B | $0.5 97.4% overvalued | N/A | $0.5 97.4% overvalued | Negative 113.9% overvalued | Negative 137.6% overvalued | (21.9%) | 121.9% | (100.0%) | (100.0%) | |
$14.0B | $11.1B | $427.2 37.8% undervalued | $483.4 56.0% undervalued | $371.0 19.7% undervalued | $382.8 23.5% undervalued | $152.3 50.9% overvalued | 107.6% | (7.6%) | (3.0%) | (1.9%) | |
$1,846.9M | $246.4M | $2,805.1 1,137.3% undervalued | N/A | $2,805.1 1,137.3% undervalued | $188.5 16.9% overvalued | $7,585.1 3,245.7% undervalued | (66.1%) | 166.1% | (100.0%) | (100.0%) |
Intrinsic Valuation Tools
Wondering how to calculate intrinsic value of a stock? Use our intrinsic value tools to simplify complex valuation concepts and save time.